Aprogen Biologics to issue 10B KRW CB
에이프로젠
007460
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2457
Risk-adjusted indicator based on 2457 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Total Convertible Bond Amount: 10,000,000,000 KRW
- • Conversion Price: 4,433 KRW/Share
- • Shares to be Issued upon Conversion: 2,255,808 Shares
- • Dilution Rate (vs. current shares): 15.65%
- • Total Potential Dilution (incl. existing CBs): 169.49%
AI Analysis Summary
Aprogen Biologics, a subsidiary of Aprogen, Inc., has decided to issue 19th series unregistered, unsecured, private convertible bonds totaling 10 billion KRW. The conversion price is 4,433 KRW per share, potentially issuing 2,255,808 new shares, representing a 15.65% dilution against current outstanding shares. The funds will be used for acquiring securities of Acro New Technology Association No. 241. Including existing outstanding convertible bonds, the total potential dilution could reach 169.49%, indicating a significant negative impact on existing shareholder value.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.